Keymed Biosciences Inc (2162)

Currency in HKD
77.25
-1.20(-1.53%)
Delayed Data·

2162 Financial Summary

Key Ratios

P/E Ratio-62.44
Price/Book5.05
Debt / Equity27.3%
Return on Equity-8.82%
Dividend Yield0.00%
EBITDA-551.07M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 76.27
(-1.27% Downside)

Earnings

Latest Release
Aug 26, 2025
EPS / Forecast
-0.30 / --
Revenue / Forecast
498.75M / --
EPS Revisions
Last 90 days

FAQ

What were Keymed Biosciences's earnings for the latest quarter?

The Keymed Biosciences EPS (TTM) is -0.98. Keymed Biosciences reported sales of 498.75, net income of -78.84, and EPS of -0.30 for the latest quarter.

What was Keymed Biosciences's net income for the latest quarter?

Keymed Biosciences's net income for the latest quarter was -78.84.

How did Keymed Biosciences's performance compare year-over-year in the latest quarter?

The company's revenue moved from 373.44 in the previous quarter to 498.75 in the latest quarter, and net income moved from -178.50 to -78.84 compared to the previous quarter.

What is Keymed Biosciences's net profit margin on a TTM basis?

Keymed Biosciences's trailing twelve months (TTM) net profit margin is -120.35%.

How does Keymed Biosciences's debt to equity ratio compare to industry standards?

Keymed Biosciences's total debt-to-equity ratio is 27.30%.

What is Keymed Biosciences's return on investment on a TTM basis?

Keymed Biosciences's trailing twelve months (TTM) return on investment (ROI) is -8.82%.

What were Keymed Biosciences's total assets and liabilities in the latest quarter?

As of the latest quarter, Keymed Biosciences reported total assets of 4,630.89 million and total liabilities of 805.34 million.

How has Keymed Biosciences's total revenue grown this year?

Keymed Biosciences's total revenue was 373.44 in the previous quarter and 498.75 in the latest quarter.

What is Keymed Biosciences's gross margin on a TTM basis?

Keymed Biosciences's trailing twelve months (TTM) gross margin is 95.19%.

What was Keymed Biosciences's revenue per share for the latest quarter?

Keymed Biosciences's revenue per share for the latest quarter was 3.67.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.